Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction
Key facts
- Who runs it
- Comphya Inc.
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- 5 Jun 2025
- Expected to end
- Apr 2027
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Activation of pro-erectile nerves within the pelvic plexus
- Record updated
- 10 November 2025
Who can take part
- Age
- 30 years to 75 years
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Men of ages between 30-75 years with indication for nerve-sparing prostatectomy surgery
- Cancer stage T1c and T2a
- Grade Groups 1 and 2 as well as low volume Grade Group 3 (Gleason score 4 + 3 = 7), as determined by biopsy (2 cores or less GG3) or single index MRI lesion of GG3 disease
- IIEF-15 erectile function domain score equal to or greater than 26
- Men interested in minimizing the effect of radical prostatectomy on erectile function
- Ability to read and understand patient information materials and willingness to sign a written informed consent
Who cannot take part
- History of previous pelvic surgery, trauma or irradiation therapy
- Patient is currently participating in another clinical investigation that would serve as a contraindication to implant a neurostimulator device to augment erectile function
- Have participated in any drug or device trial in the last 4 weeks or plan to participate in any other drug or device study during the next 24 months
- Men with neurological disease, including a history of spinal cord injury or trauma
- Failure to demonstrate adequate nocturne erectile function prioi prostatectomy (nocturnal RigiScan measure)
- History of ED, priapism and Peyronie disease
- Patient diagnosed with neurologic degenerative diseases that may negatively impact erectile functions
- Patients with insulin-dependent diabetes who suffer peripheral neuropathy or other diabetes associated complications
- IIEF-15 erectile function domain score less than 26
- Men with PSA > 20 ng/mL
- Currently have an active implantable device
- Identification of technical or clinical limitation to properly apply the use of nerve-sparing techniques during operation
- Inability to understand and demonstrate device use instructions
- Patient unwillingness to engage in sexual activity
- Possess any other characteristics that, per the investigator's judgment, may increase the risk or impair data collection for the procedure/study
- Patient is a member of a vulnerable population (Vulnerable participants include those who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, and employee volunteers)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 75 years old?
Where in United States
- Johns Hopkins HospitalBaltimore, United StatesContact: Rana HarbTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to assess if a new device is safe to use as a potential treatment for erectile dysfunction following radical prostatectomy.
Read full original descriptionShow less
The main questions it aims to answer are:
* Is the device safe? * Does the device works well? Are the participants satisfied with the device?
Participants will be implanted with the device during the ongoing prostatectomy surgery and will be asked to complete the following tasks during 6 months follow-up:
* Come to the hospital for follow-up visits, * Complete questionnaires, * Activate the device every day, * Measure erection hardness.
Researchers will compare an implanted group (participants having the device) with a control group (participants not having the device) to see if the device works well.
The 2 groups in the trial
- Implanted groupTreatment being tested
Participants in the implanted group will be implanted with the study device during ongoing prostatectomy surgery.
Treatment: Activation of pro-erectile nerves within the pelvic plexus
- Control groupNo study treatment, for comparison
Participants in the control group will undergo standard prostatectomy and will not be implanted with the study device.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Safety and Tolerability of a Novel Implantable Device for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
- Fit questions
- Built from NCT06968494, who can take part
- Record updated
- 10 November 2025